Brief: Clover Biopharmaceuticals Updates On Study Of Co's SCB-2019
21/01/2022 01:21
Jan 21 (Reuters) - Clover Biopharmaceuticals Ltd 2197.HK :
* STUDY DEMONSTRATED TWO DOSES OF CO'S SCB-2019 PROVIDES
SIGNIFICANT PROTECTION AGAINST ENTIRE SEVERITY SPECTRUM OF
COVID-19
* IN PROCESS OF SUBMITTING CONDITIONAL REGULATORY APPROVAL
APPLICATIONS TO EUROPEAN MEDICINES AGENCY, NMPA OF CHINA & WHO
Source text for Eikon: ID:nHKSbzBPWC
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune